A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

Trial Profile

A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs GSK 2879552 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Aug 2017 Planned primary completion date changed from 1 Sep 2018 to 28 Sep 2018.
    • 01 Aug 2017 Status changed from recruiting to discontinued because the risk benefit in relapsed refractory SCLC does not favor continuation of the study .
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top